At this event, he asked why we do not see any of the signs of an innovation boom in health care that we saw with personal computers and the Internet. No spectacular new companies. No surge in demand for life sciences knowhow comparable to the surge in demand for computer programming skills. As he wrote last year, he believes that the FDA’s requirement that new treatments be more efficacious than old ones has the effect of stifling disruptive innovation, in which new products first gain traction on the basis of lower price rather than better quality.
Others at the panel pointed out that it may not be the FDA that dictates the innovation pattern. It may be the fact that third party payments dominate American health care. Patients who are not paying for their own health care are not going to provide a market for radically cheaper treatments. And insurance companies are not going to want to pay for radically better treatments that cost a lot. So the only innovations that survive are incremental ones.
However, I want to go back to the original question of why we do not see an innovation boom. My thoughts:
1. My guess is that we have not yet reached a point where all the pieces are in place to produce an innovation boom. Remember that it took several decades to go from the invention of the transistor to the appearance of the personal computer.
2. We do not have an institutional breeding ground for biotech innovation. No equivalent of Bell Labs, or Xerox PARC or the Homebrew Computer Club.
3. Someone in the audience asked a provocative question about whether some other country provides a role model, which country provides a role model for health care innovation? If you thought that the only roadblocks were American customs and regulations, health care innovation would take place in other countries.